content top

2006 EVRS Congress — Cannes

CANNES RETINA FESTIVAL

Sunday, September 10

Opening of continuing Film Projection

Symposium I: Anti-Angiogenesis (Part 1)

Presiding Officer: Susan B; Bressler Chair: Ursula Schmidt-Erfurth Moderator: Tom S. Chang

Combined efficacy of intravitreal ranibizumab in two Phase III studies of CNV secondary to ARMD Anat Loewenstein
Combined Safety of Intravitreal Ranibizumab in Two Phase III Studies of CNV Secondary to ARMD Paolo Lanzetta
Two-year efficacy and safety results from the MARINA study Ursula Schmidt-Erfurth
Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 Phase III and IIIB studies of patients with CNV secondary to AMD Jean-Francois Korobelnik
Intravitreal Ranibizumab (LucentisTM) plus Verteporfin PDT for Neovascular ARMD: FOCUS 2-year Results Andrew Antoszyk
PIER: Year 1 Results of a Phase IIIB Study of Ranibizumab Efficacy and Safety in CNV Due to ARMD Prema Abraham
Pier: Year 1 FA/OCT Results in a study of Ranibizumab (Lucentis™) for CNV Due to ARMD William F. Mieler
An OCT-Guided Variable-Dosing Regimen with Lucentis™ (Ranibizumab) in Neovascular AMD: One Year Results from the PrONTO Study Philip J. Rosenfeld
Introduction of Featured Guest Lecture: Judah Folkman Presiding Officers: Didier Ducournau, Julia Haller and Gene de Juan
Potential Future Advances in Ophthalmology from Research in Tumor Angiogenesis Judah Folkman, MD

Poster Session (AMD/ANTI-ANGIOGENESIS)

Symposium II: Anti-Angiogenesis (Part 2)

Presiding Officer: Lawrence Singerman Chair: David Williams Moderators: Frank Koch

Open-label, multicenter, Phase II Study Assessing the safety and efficacy of same-day Verteporfin and liquid ranibizumab 0.5mg (PROTECT study) Sebastian Wolf
Ranibizumab (Lucentis) Vision-Specific Quality of Life Trough 24 Months in Neovascular ARMD Subjects in Marina: A Phase III Clinical Trial Tom S. Chang
Vision-Specific Quality of Life at 12 Months in Predominantly Classic Neovascular ARMD in Anchor: A Phase III Trial of Ranibizumab and Verteporfin PDT Neil M. Bressler
The Value and Cost-Effectiveness of Interventions for Subfoveal Neovascular ARMD Melissa Brown
Intravitreally Injected Anti-VEGF Drugs Exert a Biological Effect in the Fellow Eye Tongalp Tezel
Pharmacokinetics of Intravitreal Bevacizumab (Avastin) Sophie J. Bakri
Vitreous Levels of Unbound Bevacizumab and Unbound Vascular Endothelial Growth Factors in Two Human Subjects Paul M. Beer
Stability of bevacizumab (Avastin) after withdrawal into a syringe and refrigeration or freezing Colin A. McCannel
Intravitreal Bevacizumab for the treatment of CNV secondary to Ocular Histoplasmosis and Multifocal Choroiditis Sundeep Dev
Short-Term Outcomes in over 500 Intravitreal Bevacizumab Treatments for Retinal or CVD at the New York Eye & Ear Infirmary Thomas O. Muldoon
Intravitreal Bevacizumab As Isolated First Line Therapy In Patients With New Untreated CNV Membranes Alay Banker
Six-month Follow up on 50 Consecutive Patients with Intravitreal Bevacizumab Injections for Neovascular ARMD Samira Khan
Primary Intravitreal Bevacizumab (Avastin) for the Treatment of CNV secondary to ARMD: Results of the Pan-American Collaborative Retina Study Group Jans Fromow-Guerra
Intravitreal Bevacizumab (Avastin) for the Treatment of Neovascular ARMD Alessandro Castellarin
Intravitreal Bevacizumab (Avastin™) for Primary Treatment of Neovascular ARMD David F. Williams
Intravitreal Bevacizumab (Avastin) Treatment of CNV Secondary to ARMD Richard F. Spaide
Time to recurrence of ARMD-related CNV leakage after a single initial intravitreous injection bevacizumab (Avastin®): Implications for a retreatment Edgar L. Thomas
A FA/ICG analysis of the retinal/choroidal vasculature and CNV membrane complex six months following intravitreal Avastin injections Paul E. Tornambe
Intravitreal Bevacizumab Compared with PDT for Juxtafoveal CNV Membranes in ARMD Derek Barker
Combination therapy for wet ARMD using verteporfin PDT and intravitreal bevacizumab Jose Dalma-Weiszhausz
Combined PDT with Verteporfin and Intravitreal Bevacizumab for CNV in ARMD Gaurav K. Shah
Combined PDT with Verteporfin and Intravitreal Bevacizumab for Subfoveal CNV in ARMD David Misch
Combination Avastin and Reduced Fluence PDT for CNV David Callanan
Intravitreal Bevacizumab (Avastin) enhanced Pegaptanib (Macugen) therapy for CNV in ARMD: An Avastin Booster Michael J. Tolentino
Vitrectomy in Triple Therapy for CNV Frank H.J. Koch

Symposium III: Anti-Angiogenesis (Part 3)

Presiding Officer: Paul E. Tornambe Chair: Anthony Adamis Moderator: Albert Augustin

C.L.E.A.R. – IT 1: A Phase I Safety, Tolerability, and Bioactivity Study of Intravitreal VEGFTrap in Patients with Neovascular ARMD Quan Dong Nguyen
VEGF small interfering (si) RNA, for Treatment of Wet ARMD Lawrence J. Singerman
The Effects of Combined Inhibition of PDGF-B and VEGF-A Signaling in Murine Models of Ocular Neovascularization Anthony Adamis
The Role of a Selective VEGF Blockade in ARMD Thomas R. Friberg
Anecortave Acetate Clinical Update Peter K. Kaiser
Combined IVT with PDT for the treatment of CNV in ARMD Catherine Favard
The effect of Kenalog as adjunctive treatment to Visudyne in minimally classic and occult neovascular ARMD: A prospective, randomized clinical trial Tom Sheidow
Six-month Results of a Randomized, Double-Masked, Controlled Trial of IVT as an Adjunct to PDT in Predominantly Classic Neovascular ARMD. The Canadian RETINA Study David Maberley
Large case series of different types of CNV after Combination Treatment (PDT with intravitreal Triamcinolone) Albert J. Augustin
AMD-panel Moderator: Philip J. Rosenfeld

Monday, September 11

Opening of continuing Film Projection

Awards & Special Presentations Presiding Officers: Julia Haller, Gene de Juan, and George Williams

Introduction of Pyron Award Winner Brooks W. McCuen, II
Pyron Award Lecture: Evolving Concepts in Pharmacologic Vitreolysis Brooks W. McCuen, II
Introduction of Founders Award Winner Kirk H. Packo
Founders Award Lecture: Vitrectomy Technology – Where We’ve Been. Where We Are. Where We Are Going. Kirk H. Packo
Pay for Performance: A True Quality Initiative or a Means of Cost Control William L. Rich, III
American Retina Foundation Roy A. Levit
Young Phisicians Section’s Crystal Apple Award Presentation
PAT Survey Award

Poster Session (IMAGING/SURGICAL DEVICES & INSTRUMENTATION/PHARMACOLOGY/SOCIOECONOMICS)

Symposium IV: Imaging and AMD

Presiding Officer: Giovanni Staurenghi , Chair: Claude Boscher, Moderator: Gregg Kokame

Retinal Measurements with 3D-OCT Alexander C. Walsh
SOCT “Copernicus” a new diagnostic tool in retinology Jerzy Nawrocki
Active CNV Without Subretinal or Intraretinal Fluid on OCT Imaging G. Baker Hubbard
Dualing OCT Modalities: Contrasting Retinal Features Revealed by a Dual Mode High Speed Ultrahigh Resolution Spectral and Temporal OCT/SLO Imager Richard B. Rosen
Spectral Domain OCT Provides New Insight Into the Extent of Macular Pathology in ARMD Cynthia A. Toth
AMD, hypertension and potential cardiovascular risks with intravitreal Avastin injection Claude Boscher
Humanistic Burden and Health Resource Utilization in Neovascular ARMD Patients from Five Countries Gisele Soubrane
Comparison of Comorbid Conditions Between Wet ARMD Patients and a Control Cohort in the Medicare Population Gergana Zlateva
Myocardial Infarction and Cerebrovascular Accident Rates in Patients with Neovascular ARMD in a Healthcare Claims Database Emily S. West
Annual Rates of Cardiovascular Events in Medicare Neovascular ARMD Patients Tsontcho Ianchulev
Long Term Results of the Age-Related Eye Disease Study Emily Y. Chew
Vitamin Usage Patterns in the Prevention of Advanced ARMD in a Tertiary Care Population Susan B. Bressler
Effect of Initial Visual Acuity on Visual Loss in Untreated ARMD Eyes with Subfoveal Neovascularization Lucian Del Priore
Incident CNV Lesions in the Fellow Eyes of Participants with Unilateral Neovascular ARMD during the Submacular Surgery Trials Sharon D. Solomon
Quantitative OCT Sub-Analysis in Neovascular ARMD SriniVas Sadda
Treatment of Retinal Angiomatous Proliferation Lesions Associated with Pigment Epithelial Detachment with Focal Pulsed Laser Robert P. Murphy
Results of a 1 Year Study of Feeder Vessel Therapy in ARMD Giovanni Staurenghi
How many days after onset is it too late to evacuate submacular hemorrhage secondary to ARMD? Keye L. Wong
Pneumatic displacement of submacular hemorrhage- a case series Wilson Heriot
Comparison of Submacular Surgery and Natural History for the Treatment of Large Submacular Hemorrhages from MD John T. Thompson
Recurrent CNV after Macular Translocation Surgery With 360-degree Peripheral Retinectomy Claxton A. Baer (Winner 2006 B&L Retina Fellows’ Forum Research Award)
Subretinal Surgery for Peripapillary Subretinal Neovascular Membranes Gregg T. Kokame
Prolonged Choroidal Hypofluorescence following Verteporfin PDT Combined with Intravitreal Triamcinolone Acetate Injection for Age-related CNVM Jeffrey K. Luttrull
Increased Visual Acuity in Fellow Affected Eyes of Subjects Undergoing Therapy with Intravenous EVIZON™ (Squalamine lactate) for Exudative ARMD Michael Gast
Two-year Phase II/III Results (IMT002) of a Visual Prosthesis for Treatment of Central Vision Loss due to End-Stage Macular Degeneration Henry L. Hudson

Symposium V: Surgical Devices and Instrumentation (Part 1)

Presiding Officer: Mike Trese, Chair: Tarek S. Hassan, Moderator: Claus Eckardt

Evaluation of the Artificial Silicon Retina™ Device for the Treatment of Vision Loss from Retinitis Pigmentosa John S. Pollack
Chronic retinal chip implant in blind patients with retinitis pigmentosa Gisbert Richard
Results from a Chronically Implanted 16-Channel Epiretinal Prosthesis in Blind Subjects Robert J. Greenberg
Shedding More Light on Endoillumination David R. Chow
Initial Clinical Experience with a Patterned Scanning Laser (PASCAL) for the Treatment of Retinal Diseases Julia A. Haller
Results of Ophthalmic Surgical Training Using a High-fidelity Surgical Simulator Coupled with a Curriculum Based on Task Breakdown and Analysis Michael Grodin
Cannulation of the Suprachoroidal Space: Drug Delivery and Pharmacokinetics of Triamcinolone Acetonide and Bevacizumab Timothy W. Olsen
Enzymatic Alteration of Vitreous Cavity Oxygen Levels Michael T. Trese
20 Gauge Sutureless Transconjunctival Vitrectomy Daniel Polya
Transconjunctival 20-G Sutureless Vitrectomy Mikael Sebag
25 Gauge Vitrectomy: Outcomes and Complications Carl Regillo
Complications of 25-gauge Vitrectomy Surgery Robert A. Mittra
A Head-to-Head Intraoperative Clinical Comparison of Flow Rates: Electric vs. Pneumatic 25-gauge High-Speed Vitreous Cutters Tarek S. Hassan
23-Gauge Vitrectomy as an effective and safe alternative for sutureless vitreous surgery Keith A. Warren
23-Gauge Vitrectomy in 100 Eyes: Short-Term Visual Outcomes and Complications Harinderjit Singh
Further experience with 23-gauge transconjunctival vitrectomy Claus Eckardt
23g Sutureless Vitrectomy: When and Why? Zoran Tomic
A new 23 Gauge Vitrectomy System George A. Williams
New Devices for Vitreoretinal Surgery Carl C. Awh
Surgical Devices and Instrumentation Panel Discussion Moderator: Carl C. Awh

Tuesday, September 12

Opening of continuing Film Projection

Symposium VI: Surgical Devices and Instrumentation (Part 2)

Presiding Officer: Suber Huang, Chair: Steve Charles, Moderator: Oswaldo Brasil, Sr.

Comparison Of Wound Leakage Between Straight And Tunnel Scleral Incisions After 25 Gauge Vitrectomy Luiz Hagemann
The integrity of wound closure after 23 versus 25 gauge sutureless vitrectomy Oswaldo Moura Brasil, Jr.
Unfavorable Surgical Events in 25 vs. 20 Gauge Vitreous Surgery Saad A. Shaikh
Comparison of visual recovery time in patients undergoing 20g and 25 gauge vitreous surgery Suber S. Huang
Vitreous Dynamics: The New Solid Development Concept. Vitreous Flow Analysis in 20, 23 and 25 Gauge Cutters Octaviano Magalhaes
Fluid dynamics among different 25-gauge systems: principles for use in vitreoretinal surgery Michel E. Farah
Improved understanding of TSV-25g Vitrectomy system: Qualitative High Speed Video Analysis Of Vitreous Movement Around Aperture of Vitreous Cutters Mark S. Humayun
Interface Vitrectomy Steve T. Charles
Passive Removal of Silicone Oil with 25-Gauge Transconjunctival Sutureless Vitrectomy Instruments Ziya Kapran

Symposium VII: Retinal Vascular Disease and Oncology

Presiding Officer: Suber Huang, Chair: Steve T. Charles, Moderator: Oswaldo Brasil, Sr.

Reversal of Ischemic CRVO: A Novel Technique of Multiple Retinal Vein Decompression and Chorioretinal Venous Anastomosis Calvin A. Grant
Radial optic neurotomy plus IVT with and without ILM peeling for CRVO Jose Garcia-Arumi
Safety Profile of Various Steroids on Retinal Cells In Vitro Baruch D. Kuppermann
Pegaptanib Sodium for the Treatment of ME Following CRVO John Wells
Short Term Visual and Anatomic Outcomes Following Intravitreal Bevacizumab for ME Secondary to CRVO Jose A. Roca
Intravitreal Bevacizumab For Treatment Of ME In Central And BRVO Ajay Dudani
Ranibizumab (Lucentis) in ischemic CRVO: intermediate OCT and visual results from the RAVE trial Matthew S. Benz
Retinoblastoma Tumor Vascular Heterogeneity: A Model for Angiogenic Vacular Maturation and Implications for Vascular Targeting Therapy Timothy G. Murray
Standard and High Resolution Echographic Features of Melanocytoma Amy C. Schefler

Poster Session (DIABETIC RETINOPATHY/RETINAL VASCULAR DISEASE & ONCOLOGY/MACULAR SURGERY)

Symposium VIII: Diabetic Retinopathy (Part 1)

Presiding Officer: J. Fernando Arevalo, Chair: Athanasios Nikolakopoulus, Moderator: Robert L. Avery

Clinical Detection of DME Using the Automated Retinal Imaging System Antonio P. Ciardella
Factors Influencing Utilization of a Telemedicine Diabetic Retinopathy Assessment Program in the Primary Care Setting Ingrid E. Zimmer-Galler
Diurnal Variation in Retinal Thickening Measured by OCT Michel J. Shami
Subthreshold Micropulse Diode Laser Photocoagulation in the treatment of diabetic clinically significant ME Neelakshi Bhagat
VEGF small interfering (si) RNA, Cand5, for Treatment of DME Jonathan L. Prenner
Three-Year Results of a Multicenter Clinical Trial of the Fluocinolone Acetonide Intravitreal Implant to Treat DME Dean Eliott
The I-vation Sustained Release Drug Delivery System and Intravitreal Implant Eugene de Juan, Jr.
The Effect of the Oral PKC ? Inhibitor Ruboxistaurin on Visual Loss and DME Ronald P. Danis
The Effect of an Epiretinal Membrane on IVT Treatment for DME Parin S. Gohel
Predictive factors for visual outcome after IVT acetonide injection for DME Rishi Singh
Pegaptanib Sodium in Diabetic Retinopathy: Improvements in DME, RNV, and Severity of Diabetic Retinopathy Victor Hugo Gonzalez
OCT Following Pegaptanib Therapy in Diabetics: a Bioanatomic Study of DME David R. Guyer
Intravitreal injection versus systemic Bevacizumab(Avastin) Therapy for DME Murat Oncel
Interim Results of the R.E.A.D. Study: Ranibizumab for Edema of the Macula in Diabetes Diana V. Do
Primary Intravitreal Bevacizumab (Avastin) for the Treatment of DME: Results of the Pan-American Collaborative Retina Study Group J. Fernando Arevalo
Intravitreal Bevacizumab (Avastin) in the Treatment of PDR Robert L. Avery
Injection of Intravitreal Avastin before Vitrectomy Surgery in the treatment of Severe PDR Stanislao Rizzo
A Simple Predictor of Vitrase® Efficacy for BCVA Improvement in Patients with Diabetes and Severe Vitreous Hemorrhage Abdhish R. Bhavsar
Vitrase for Vitreous Hemorrhage Revisited Michael A. Singer
25 Gauge Vitrectomy for Advanced PDR: A Consecutive Case Series Including Complex RD Firas M. Rahhal
Diabetic traction detachment treated with bimanual 25g sutureless surgery (Is silicon oil necessary?) Athanasios Nikolakopoulos
Reoperation After Diabetic Vitrectomy: Rate, Indications, Visual Outcomes, and Complications in an Urban Academic Medical Center Julie Gasperini
Posterior Juxtascleral Injection of Triamcinolone Acetonide for Cases of Diabetic ME Unresponsive or Unamenable to Laser Treatment Franco M. Recchia
Vitrectomy for DME: study design and preliminary results of VIDE Study, an Italian clinical trial Barbara Parolini

Symposium VIII: Diabetic Retinopathy (Part 2)

Panel Discussion Moderator: Harry W. Flynn Panelists: Tarek S. Hassan, Rodrigo Jorge, Frank HJ Koch, Brooks W. McCuen, II, Robert P. Murphy, Georgiy Stolyarenko

Symposium IX: Macular Surgery

Presiding Officer: Claudio Azzolini , Chair: Fabio Patelli , Moderator: Keye Wong

Posterior RD and retinoschisis without a MH in highly myopic eyes: Clinical findings and management Hassan Mortada
Myopic Traction Maculopathy: A Slowly Progressive and Treatable Disease Giacomo A. Panozzo
25 Gauge Macular Surgery: Results and Complications Fabio Patelli
Surgical Treatment of Macular Pucker: Multicenter Clinical Trial Claudio Azzolini
Outcomes of 25 gauge transconjonctival membrane peeling combined with sutureless phaco/IOL surgery Jean-Paul Berrod
Combined Phacoemulsification and Vitrectomy for MH Repair Ioannis Theocharis
Prospective randomized clinical trial comparing face down position and semi seated position after surgery for idiopathic full-thickness MH Alexandre Guillaubey
ILM peeling prevents late reopening of closed MH Thierry C. Verstraeten
25 Gauge Transconjunctival Sutureless Vitrectomy for MH repair: how can we resolve technique-related problems? Federica Genovesi-Ebert
Results of Surgical Management of Senile MH by 25-Gauge Trans-Conjunctival Sutureless Vitrectomy Compared to Standard Vitrectomy Systems C. Christopher Brown
Idiopathic MH Following Pars Plana Vitrectomy For RD Francesco Boscia

Wednesday, September 13

Opening of continuing Film Projection

Symposium X: Retinal Detachment

Presiding Officer: Giampaolo Gini, Chair: Klaus Lucke, Moderator: Masoud Soheilian

The Value and Cost-Effectiveness of Vitreoretinal Interventions Gary C. Brown
Rhegmatogenous RD in myopic eyes after LASIK. Characteristics, surgical management and functional outcomes Anna Boixadera
Use of 25-Gauge Pars Plana Vitrectomy Surgery for Primary Repair of Rhegmatogenous RD Amitabh Bharadwaj
Visual and Anatomic Outcomes of Pneumatic Retinopexy Daniel B. Roth
Results of Pneumatic Retinopexy in Phakic Eyes – A Prospective Comparison of the Clinical Trial Group Inclusion Criteria and Extended Criteria Stephen M. Conti
Optic Pit RD – Attempt at a Unifying Theory Klaus Lucke
Multiples Macular RD After successful Buckle Surgery: Infrared, Autofluorescence, oct and Microperimetric features Francesco Faraldi
Incidence of RD after macular surgery: a retrospective study of 634 cases Catherine Creuzot
Cataract Surgery and Vitrectomy for PVR: comparaisons Between Internal Tamponades and Lens Removal Techniques Marcio B. Nehemy
Triamcinolone Acetonide in Silicone-filled Eyes as Adjunctive Treatment for PVR: A Randomized Clinical Trial Hamid Ahmadieh
Effect of Intraoperative 5-Fluorouracil and Low Molecular Weight Heparin on the Outcome in High-Risk PVR Guruprasad S. Ayachit
Primary Vitrectomy in the Treatment of RD in Highly Myopic Eyes with Axial Length Over 30mm Gregoire Minoyan

Symposium XI: Trauma

Presiding Officer: Giampaolo Gini, Chair: Klaus Lucke , Moderator: Masoud Soheilian

Poster Session (PEDIATRIC AND INFLAMMATORY DISEASE/HEREDITARY RETINAL DISEASE & GENETICS/RETINAL DETACHMENT/TRAUMA)

Symposium XII: Pediatrics and Inflammatory Disease

Presiding Officer: Harry Flynn, Chair: Silvia Bopp, Moderator: Dan Martin

Screening for retinopathy in the pediatric sickle cell patient population Harmeet Gill
PFV: Clinical Spectrum and Therapeutic Approach Silvia Bopp
Telemedicine Screening for Retinopathy of Prematurity: The Stanford Experience (SUNDROP) Steven R. Sanislo
Safety and efficacy of intravitreal bevacizumab for retinopathy of prematurity Hugo Quiroz-Mercado
Anti-VEGF Therapy for Pediatric Retinopathies: Which Case is the Right Case? Kimberly A. Drenser
Endophthalmitis in the Newborn Kristen Hartley
A 2006 Update on the Risks Associated with Intravitreous Injection and Guidelines for Safe Administration Emmett T. Cunningham
Acute-onset Endophthalmitis Following Clear Corneal Cataract Surgery (1996-2005): Clinical Features, Microbiology and Visual Outcomes Geeta Lalwani
Early Onset Endophthalmitis Caused by Aspergillus Species Following Cataract Surgery Harry W. Flynn, Jr.
25-Gauge Vitrectomy Management of Severe Post-Cataract Surgery Endophthalmitis Flavio A. Rezende
Complete and Early Vitrectomy for Eyes with Postoperative Endophthalmitis Ferenc Kuhn
In-office And Bedside Sutureless Vitrectomy for The Diagnosis Of Uveitis Robert G. Josephberg
Three-Year Results of a Multi-Center Clinical Trial of Fluocinolone Acetonide Intravitreal Implants to Treat Posterior Uveitis Daniel F. Martin

Symposium XIII: Future Directions

Presiding Officer: Harry W. Flynn, Chair: Silvia Bopp, Moderator: Daniel F. Martin

Sub-retinal injection of Bevacizumab (Avastin) in treating neovascular ARMD, 25 gauge approach Ehab El-Rayes
Rationale for Genistein in the Prevention and Treatment of Diabetic Retinopathy Michael J. Cooney
Application of Proteomic Analysis to Characterize the Molecular Pathways of the Vitreous and Retina in Health and Disease Bert M. Glaser
Ultra-Wide Angle Fluorescein Angiographic Evaluation of the Retinal Periphery in the Management of Retinal Vascular Diseases Steven D. Schwartz
New Pharmacologic Treatments for Retinal Disease: A Venture Capital Perspective Gilbert H. Kliman

content top